Tumor-Intrinsic Nuclear β-Catenin Associates with an Immune Ignorance Phenotype and a Poorer Prognosis in Head and Neck Squamous Cell Carcinomas.
PD-L1
head and neck
squamous cell carcinoma
tumor infiltrating lymphocytes
β-catenin
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
30 Sep 2022
30 Sep 2022
Historique:
received:
29
08
2022
revised:
27
09
2022
accepted:
27
09
2022
entrez:
14
10
2022
pubmed:
15
10
2022
medline:
18
10
2022
Statut:
epublish
Résumé
Activation of WNT/β-catenin signaling has been associated with a non-T-cell-inflamed tumor microenvironment (TME) in several cancers. The aim of this work was to investigate the relationship between β-catenin signaling and TME inflammation in head and neck squamous cell carcinomas (HNSCCs). Membrane and nuclear β-catenin expression, PD-L1 expression, and CD8+ tumor-infiltrating lymphocyte (TIL) density were jointly evaluated by immunohistochemistry in a series of 372 HPV-negative HNSCCs. Membrane β-catenin levels decreased in carcinomas compared to the normal epithelium. Positive nuclear β-catenin was detected in 50 tumors (14.3%) and was significantly associated with a low CD8+ TIL density (168 cells/mm
Identifiants
pubmed: 36232859
pii: ijms231911559
doi: 10.3390/ijms231911559
pmc: PMC9569731
pii:
doi:
Substances chimiques
B7-H1 Antigen
0
beta Catenin
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Instituto de Salud Carlos III
ID : 16/00280
Organisme : Instituto de Salud Carlos III
ID : PI19/00560
Organisme : Instituto de Salud Carlos III
ID : PI19/00098
Organisme : Centro de Investigación Biomédica en Red de Cáncer
ID : CB16/12/00443
Organisme : Centro de Investigación Biomédica en Red de Cáncer
ID : CB16/12/00390
Organisme : Fundación Merck Salud
ID : 17-CC-008
Organisme : Gobierno del Principado de Asturias
ID : IDI/2021/000079
Organisme : Asociación Española Contra el Cáncer
ID : AECC; 2019/ INVES19001ALVA
Références
Front Immunol. 2019 Sep 26;10:2293
pubmed: 31616443
J Clin Invest. 2017 Aug 1;127(8):2930-2940
pubmed: 28650338
Cancer Res. 2015 Jun 1;75(11):2139-45
pubmed: 25977340
J Exp Med. 2020 Nov 2;217(11):
pubmed: 32860047
J Clin Oncol. 2015 Oct 10;33(29):3293-304
pubmed: 26351330
J Immunother Cancer. 2019 Jul 15;7(1):184
pubmed: 31307547
Onco Targets Ther. 2018 Apr 09;11:2029-2036
pubmed: 29670378
Cancer Discov. 2021 Oct;11(10):2413-2429
pubmed: 34518209
Trends Cell Biol. 2019 Jan;29(1):44-65
pubmed: 30220580
Int J Cancer. 2014 Jan 15;134(2):487-92
pubmed: 23824638
Nat Rev Cancer. 2018 Mar;18(3):139-147
pubmed: 29326431
Oncol Lett. 2021 Mar;21(3):203
pubmed: 33574942
Cancer Discov. 2022 Jan;12(1):31-46
pubmed: 35022204
Mol Cell Biol. 2002 Feb;22(4):1172-83
pubmed: 11809808
Immunity. 2018 Dec 18;49(6):1148-1161.e7
pubmed: 30552023
Cancer Epidemiol. 2015 Feb;39(1):37-41
pubmed: 25468644
Nat Rev Cancer. 2018 May;18(5):269-282
pubmed: 29497144
Clin Cancer Res. 2019 May 15;25(10):3074-3083
pubmed: 30635339
Cancer Treat Rev. 2018 Jan;62:50-60
pubmed: 29169144
CA Cancer J Clin. 2015 Mar;65(2):87-108
pubmed: 25651787
Biomed Pharmacother. 2019 Jul;115:108921
pubmed: 31078045
Cancer Immunol Immunother. 2020 Oct;69(10):2089-2100
pubmed: 32448984
Nature. 2015 Jul 9;523(7559):231-5
pubmed: 25970248